Is there a relationship between hematological inflammatory parameters and age-related macular degeneration?

Mine Karahan, Leyla Hazar, Seyfettin Erdem, Sedat Ava, Mehmet Emin Dursun, Atılım Armağan Demirtaş and Uğur Keklikçi

Abstract

Purpose: We aimed to analyze blood inflammation parameters in patients with age-related macular degeneration (AMD).

Methods: In this retrospective study, patients were divided into three groups: wet-type AMD \( n = 60 \), dry-type AMD \( n = 60 \), and healthy controls \( n = 71 \). The laboratory and demographic data of the patients were analyzed. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were calculated manually.

Results: The mean NLR was \( 2.26 \pm 1.42 \) in the dry-type AMD group, \( 3.90 \pm 1.65 \) in the wet-type AMD group, and \( 1.84 \pm 0.61 \) in the control group \( (p < 0.001) \). The mean MLR was \( 0.30 \pm 0.20 \) in the dry-type AMD group, \( 0.47 \pm 0.31 \) in the wet-type AMD group, and \( 0.28 \pm 0.14 \) in the control group \( (p < 0.001) \). The mean PLR was \( 129.31 \pm 79.82 \) in the dry-type AMD group, \( 156.67 \pm 83.99 \) in the wet-type AMD group, and \( 135.59 \pm 58.68 \) in the control group \( (p = 0.101) \). Receiver operating characteristic (ROC) curve analyses revealed that the area under the curve (AUC) for NLR and MLR was \( 0.920 \) and \( 0.717 \), respectively, for wet-type AMD. The sensitivity and specificity of NLR for wet-type AMD were \( 64\% \) and \( 93\% \), respectively, whereas MLR was \( 63\% \) and \( 75\% \), respectively.

Conclusion: Simple blood tests revealed that NLR and MLR were significantly higher in patients with wet-type AMD than in patients with dry-type AMD and healthy controls, which implies low-grade inflammation.

Keywords: age-related macular degeneration, monocyte-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio

Introduction

Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide. AMD is caused by an accumulation of drusen in the macula and results in severe visual impairment.\(^1\) There are two subgroups of AMD: dry type and wet type. In dry-type AMD, progressive deterioration of the macula and consequent loss of central vision occur. Wet-type AMD is caused by the development of abnormal blood vessels under the macula, causing fluid and blood leakage.\(^2\) Vascular endothelial growth factor (VEGF) plays an important role in the formation of blood vessels in the eye in neovascular AMD, so anti-VEGF drugs are used in the treatment of AMD.\(^3\) Progression of wet-type AMD is more rapid and can cause severe vision loss within a few months if left untreated.\(^4\)

Although wet-type AMD accounts for only 10\% of cases, it is the cause of 90\% of cases of severe visual loss due to AMD. The risk factors for AMD include older age, female sex, a family history of AMD, genetic factors (e.g. complement factor H
polymorphisms), smoking, exposure to sunlight, obesity, hypertension, and hypercholesterolemia.5

Inflammation results from a complex network of interactions involving cells associated with the immune system, including neutrophils, lymphocytes, and macrophages. Clinical studies have shown that the number of lymphocytes, neutrophils, and white blood cells and the proportion of these cells may reflect chronic inflammation.6 It has been suggested that the neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation. Therefore, NLR has been investigated in several studies as a marker of systemic immunity. It is believed that NLR may be an independent prognostic factor in several solid tumors and may be associated with chronic inflammatory diseases.7

Inflammation, oxidative stress, and endothelial dysfunction are thought to increase the severity and incidence of AMD. Many studies have shown the relationship between the incidence of AMD and C-reactive protein (CRP) level, tumor necrosis factor-α receptor, and oxidative stress.8–12 Numerous recent studies have shown that NLR and PLR are indicators of systemic inflammation.13–15

This study aimed to analyze the importance of inflammation in the pathophysiology of the disease by comparing NLR, monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) in patients with AMD in our clinic and compare the subtypes of AMD.

Methods
Data from 120 patients in the AMD groups (60 in the dry-type AMD group and 60 in the wet-type AMD group) and 71 in the control group between January 2016 and January 2019 was examined retrospectively. The control group consisted of patients who underwent cataract surgery and had no other eye diseases.

As we provide healthcare services in a tertiary hospital, AMD patients can both directly apply to our clinic and be referred from other healthcare institutions. For anti-VEGF applications, drug approval from the tertiary health institution is required. For this reason, we have a large archive of AMD patients. The patients were divided into three groups: wet-type AMD, dry-type AMD, and a healthy control group. All ophthalmologic examination records, including anterior and posterior segment findings, best-corrected visual acuity, and intraocular pressure, were examined, and data were recorded. Existing optical coherence tomography (Heidelberg Engineering, Heidelberg, Germany) and fundus fluorescein angiography images were analyzed. Dry-type AMD was indicated by at least one eye with drusen or geographic atrophy, and wet-type AMD was indicated as neovascular membrane, disciform scar, or pigment epithelial detachment (Figures 1–3). Patients and control group participants without detailed ophthalmologic examination and whole blood examinations, patients with hematologic disease, patients with acute and chronic infection, patients with diabetes or obesity, patients with another retinal disorder or glaucoma, patients with chronic lung disease, and patients using steroids were excluded from the study. Smoking was also recorded.

Red blood cells, white blood cells, neutrophils, monocytes, lymphocytes, and platelets were counted in whole blood. Blood tests were performed on a Mindray BC 6800 (Mindray Building, High-tech Industrial Park, Nanshan, Shenzhen, China) device with original kits. The BC 6800 hematology analyzer used sheath flow impedance, laser scatter, and SF Cube analysis technology. NLR was obtained by dividing the neutrophil count by the lymphocyte count, and PLR was obtained by dividing the platelet count by the lymphocyte count. The MLR was obtained by dividing the monocyte count by the lymphocyte count.
IBM SPSS Statistics software version 22 (IBM Corp., Chicago, IL, USA) was used to analyze the data. Continuous variables were reported as mean ± standard deviation, and categorical variables were reported as frequency and percentage. The difference between the means of the continuous variables was tested via analysis of variance (ANOVA) and post hoc Bonferroni test. We analyzed receiver operating characteristic (ROC) curves analysis to specify the sensitivity and specificity of NLR and MLR values with the optimal cutoff value for wet-type AMD prediction. A $p$ value of $<0.05$ was considered statistically significant in all analyses.

**Results**

The mean age was $74.78 \pm 7.59$ years in the dry-type AMD group, $78.03 \pm 8.60$ years in the wet-type AMD group, and $75.25 \pm 9.83$ years in the control group. Of the 191 participants included in the study, 87 (45.6%) were women, and 104 (54.4%) were men (Table 1).

The mean NLR was $2.26 \pm 1.42$ in the dry-type AMD group, $3.90 \pm 1.65$ in the wet-type AMD group, and $1.84 \pm 0.61$ in the control group ($p<0.001$). The mean PLR was $129.31 \pm 79.82$ in the dry-type AMD group, $156.67 \pm 83.99$ in the wet-type AMD group, and $113.54 \pm 68.44$ in the control group ($p<0.001$). The ROC curve analysis showed that the AUC for NLR was 0.91 (95% CI: 0.88-0.95) for wet-type AMD prediction, and the AUC for MLR was 0.92 (95% CI: 0.89-0.95). The optimal cutoff values for NLR and MLR were 2.5 and 130, respectively.

**Table 1.** Demographic data of patients.

| Characteristic       | Dry-type AMD ($n = 60$) | Wet-type AMD ($n = 60$) | Control ($n = 71$) | $p$ value |
|----------------------|-------------------------|-------------------------|--------------------|-----------|
| Age (years)          | $74.78 \pm 7.59$        | $78.03 \pm 8.60$        | $75.25 \pm 9.83$   | 0.09*     |
| Sex ($n$)            |                         |                         |                    |           |
| Female               | 22                      | 26                      | 39                 | 0.103†    |
| Male                 | 38                      | 34                      | 32                 |           |
| Smoking ($n$)        | 8                       | 9                       | 11                 | 0.937†    |

AMD, age-related macular degeneration.

*One-way analysis of variance was used.

†Chi-square test was used.
The mean MLR was 0.30 ± 0.20 in the dry-type AMD group, 0.47 ± 0.31 in the wet-type AMD group, and 0.28 ± 0.14 in the control group (p < 0.001). While there was a significant difference between the groups in terms of neutrophil and lymphocyte counts (p < 0.001 and p = 0.049, respectively), monocyte and platelet counts were similar in all three groups (p = 0.487 and p = 0.095, respectively). There were statistically significant differences between the three groups with respect to NLR and MLR (Table 2). When multiple comparisons with post hoc tests were made, the NLR values were significantly higher in wet-type AMD than in dry-type AMD and healthy control groups (p < 0.001). Similarly, MLR values were higher in wet-type AMD than in dry-type AMD and healthy control groups (p < 0.001) (Table 3).

The area under the curve (AUC) values for NLR and MLR to distinguish wet-type AMD from dry-type AMD and healthy control groups were found to be 0.920 and 0.717, respectively (Figure 4(a) and (b)).

A cutoff value of >3.07 for NLR was found to be a distinctive parameter in wet-type AMD. The sensitivity and specificity for this cutoff point were 64% and 93%, respectively.

A cutoff value of >0.31 for MLR was found to be a distinctive parameter in wet-type AMD. The

| Table 2. Neutrophil, lymphocyte, monocyte, platelet, NLR, PLR, and MLR in patients with dry- and wet-type AMD and control group. |
|---------------------------------------------------------------|
| **Dry-type AMD** | **Wet-type AMD** | **Control** | **p value*** |
| Neutrophil | 4.80 ± 2.35 | 6.09 ± 1.39 | 4.90 ± 1.97 | <0.001 |
| Lymphocyte | 2.40 ± 1.99 | 1.83 ± 0.47 | 2.10 ± 0.79 | 0.049 |
| Monocyte | 0.58 ± 0.23 | 0.58 ± 0.20 | 0.52 ± 0.19 | 0.487 |
| Platelet | 235.35 ± 69.50 | 246.46 ± 58.09 | 260.94 ± 71.42 | 0.095 |
| NLR (mean ± SD) | 2.26 ± 1.42 | 3.90 ± 1.65 | 1.84 ± 0.61 | <0.001 |
| PLR (mean ± SD) | 129.31 ± 79.82 | 156.67 ± 83.99 | 135.59 ± 58.68 | 0.101 |
| MLR (mean ± SD) | 0.30 ± 0.20 | 0.47 ± 0.31 | 0.28 ± 0.14 | <0.001 |

AMD, age-related macular degeneration; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SD, standard deviation.

*One way analysis of variance was used, p < 0.05 was statistically significant.

| Table 3. Multiple comparisons between groups. |
|---------------------------------------------------------------|
| **Neutrophil** | **p value** | **95% CI (lower bound-upper bound)** |
| Control–Wet-type AMD | 0.002 | -2.01 to -0.36 |
| Control–Dry-type AMD | 1.00 | -0.72 to 0.93 |
| Wet-type AMD–Dry-type AMD | 0.001 | 0.43 to 2.15 |
| **Lymphocyte** | 0.664 | -0.26 to 0.79 |
| Control–Wet-type AMD | 0.515 | -0.83 to 0.22 |
| Wet-type AMD–Dry-type AMD | 0.040 | -1.12 to -0.01 |
| **NLR** | 0.001 | -2.59 to -1.51 |
| Control–Wet-type AMD | 0.174 | -0.96 to 0.11 |
| Wet-type AMD–Dry-type AMD | 0.001 | 1.06 to 2.19 |
| **MLR** | 0.001 | -0.28 to -0.09 |
| Control–Wet-type AMD | 0.982 | -0.12 to 0.06 |
| Wet-type AMD–Dry-type AMD | 0.001 | 0.06 to 0.26 |

AMD, age-related macular degeneration; CI, confidence interval; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio. Post hoc Bonferroni test, p<0.05 was statistically significant.
sensitivity and specificity for this cutoff point were 63% and 75%, respectively (Table 4).

**Discussion**

In our study, NLR and MLR were found to be higher in the wet-type AMD group than in the dry-type AMD and the control groups, and this difference was statistically significant. However, PLR was found to be higher in the wet-type AMD group than in the dry-type AMD and control groups, but this difference was not statistically significant.

AMD is a complex, chronic, progressive, neurodegenerative disease with multifactorial etiology. Chronic inflammation and hypoxia leading to oxidative stress cause aging of the normal retina. Continued oxidative stress causes inflammation and tissue damage. Complement system activation in Bruch’s membrane and activation of the microglia between the retina and choroid play an important role in choroidal neovascular membrane formation. Studies are underway to investigate the effect of systemic inflammation on the possible mechanism of dry- and wet-type AMD.16

NLR has been shown to be associated with the activity and outcome of chronic inflammatory diseases, such as arthritis, systemic hypertension, diabetes mellitus (DM), and chronic obstructive pulmonary disease.7,17,18

In their meta-analysis, Niazi and colleagues19 found a strong correlation between high NLR and wet-type AMD, but found no difference between the dry-type AMD and control groups. Ilhan and colleagues found a higher NLR in patients with AMD than in the control group. This study also found a significant difference between AMD groups and NLR associated with age and the severity of the disease and a marker of inflammation in AMD.20 Subhi and Lykke Sørensen21 found that systemic leukocyte activity correlated with the early stage of AMD in patients with wet-type AMD, and systemic leukocyte activity was correlated with lesion size and best-corrected visual acuity.

Kurtul and Ozer22 found an independent relationship between wet-type AMD and increased NLR with 73% sensitivity and 60% specificity. Several studies have shown that NLR and PLR are associated with the severity of the disease and can be used as a biomarker of inflammation in AMD.19–22

Our study is rare in that it evaluated MLR values in wet- and dry-type AMD in addition to NLR and PLR. We found statistically significant differences between the groups in terms of NLR and MLR. NLR and MLR values were significantly

![Figure 4](image_url)
higher in wet-type AMD than in dry-type AMD and healthy control groups. This indicates a relationship between systemic inflammation and wet-type AMD. On the other hand, ROC analyses revealed a 64% sensitivity for NLR and 63% sensitivity for MLR in wet-type AMD.

Pinna and colleagues found a significantly lower number of white blood cells in patients with AMD compared with the control group, and no statistically significant difference between the control group and male patients with AMD in terms of NLR and PLR. Wu and colleagues investigated the relationship between patients with AMD and healthy controls in terms of hemostatic factors and inflammatory markers and found no association between inflammatory markers and AMD.

Our study has several limitations, including its retrospective design, the fact that the early and advanced stages of the disease are not mentioned separately but are examined under a single heading, and the fact that there were insufficient data on patients’ history of medication use. In addition, as our clinic does not offer indocyanine green angiography, it cannot be stated that we have excluded polypoid choroidal vasculopathy for a limited number of patients. Finally, we did not evaluate the effect of cataracts on inflammation parameters in this study, and we consider this a limitation.

In conclusion, we found that NLR and MLR were different between wet-type AMD and dry-type AMD and healthy control groups. Therefore, these differences indicate inflammation in patients with wet-type AMD. Further studies with a larger sample size are required.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

| Marker | AUC   | 95% CI  | p value | Cutoff | Sensitivity (%) | Specificity (%) |
|--------|-------|---------|---------|--------|----------------|-----------------|
| NLR    | 0.920 | 0.88–0.95 | <0.001 | >3.07  | 64             | 93              |
| MLR    | 0.717 | 0.63–0.79  | <0.001 | >0.31  | 63             | 75              |

AUC, area under the curve; CI, confidence interval; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; ROC, receiver operating characteristic. *P*< 0.05 was statistically significant.

**Funding**
The authors received no financial support for the research, authorship, and/or publication of this article.

**Ethics statement**
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the local ethics committee (Diyarbakir Training and Research Hospital, decision no. 2019/263). All patients gave written informed consent.

**ORCID iDs**
Leyla Hazar https://orcid.org/0000-0002-8206-781X
Seyfettin Erdem https://orcid.org/0000-0001-5742-1293
Atılım Armağan Demirtaş https://orcid.org/0000-0002-6504-8385

**References**
1. Subramani S, Khor SE, Livingstone BI, et al. Serum uric acid levels and its association with Age-Related Macular Degeneration (ARMD). Med J Malaysia 2010; 65: 36–40.
2. Bhatt P, Narvekar P, Lalani R, et al. An in vitro assessment of thermo-reversible gel formulation containing sunitinib nanoparticles for neovascular age-related macular degeneration. AAPS Pharm Sci Tech 2019; 20: 281.
3. Bhatt P, Kelly S and Sutariya V. Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications. Ther Deliv 2019; 10: 737–747.
4. De Jong PTVM. Age-related macular degeneration. N Engl J Med 2006; 355: 1474–1485.
5. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC Ophthalmol* 2010; 10: 31.

6. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* 2006; 6: 173–182.

7. Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. *Eur Respir Rev* 2018; 27: 170113.

8. Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. *Arch Ophthalmol* 2005; 123: 1501–1506.

9. Klein R, Knudtson MD, Klein BEK, et al. Inflammation, complement factor H, and age-related macular degeneration. The multi-ethnic study of atherosclerosis. *Ophthalmology* 2008; 115: 1742–1749.

10. Mitta VP, Christen WG, Glynn RJ, et al. C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. *JAMA Ophthalmol* 2013; 131: 507–513.

11. Brantley MA Jr, Osborn MP, Sanders BJ, et al. Plasma biomarkers of oxidative stress and genetic variants in age-related macular degeneration. *Am J Ophthalmol* 2012; 153: 460–467.

12. Machaliniska A, Kawa MP, Marlicz W, et al. Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis. *Acta Ophthalmol* 2012; 90: 695–703.

13. Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. *Clin Res Hepatol Gastroenterol* 2012; 36: 491–497.

14. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol* 2008; 102: 653–657.

15. Yayla C, Açıkgöz SK, Yayla KG, et al. The association between platelet-to-lymphocyte ratio and inflammatory markers with the severity of aortic stenosis. *Biomark Med* 2016; 10: 367–373.

16. Nita M, Grzybowski A, Ascaso FJ, et al. Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). *Mediators Inflamm* 2014; 2014: 930671.

17. Fu H, Qin B, Hu Z, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. *Clin Lab* 2015; 61: 269–273.

18. Mertoglu C and Gunay M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. *Diabetes Metab Syndr* 2017; 11: S127–S131.

19. Niazi S, Krogh Nielsen M, Sørensen TL, et al. Neutrophil-to-lymphocyte ratio in age-related macular degeneration: a systematic review and meta-analysis. *Acta Ophthalmol* 2019; 97: 558–566.

20. Ilhan N, Daglioglu MC, Ilhan O, et al. Assessment of neutrophil/lymphocyte ratio in patients with age-related macular degeneration. *Ocul Immunol Inflamm* 2015; 23: 287–290.

21. Subhi Y and Lykke Sørensen T. New neovascular age-related macular degeneration is associated with systemic leucocyte activity. *Acta Ophthalmol* 2017; 95: 472–480.

22. Kurtul BE and Ozer PA. The relationship between neutrophil-to-lymphocyte ratio and age-related macular degeneration. *Korean J Ophthalmol*; 30: 377–381.

23. Pinna A, Porcu T, D’Amico-Ricci G, et al. Complete blood cell count–derived inflammation biomarkers in men with age-related macular degeneration. *Ocul Immunol Inflamm* 2019; 27: 932–936.

24. Wu KHC, Tan AG, Rochtchina E, et al. Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study. *Invest Ophthalmol Vis Sci* 2007; 48: 1983–1988.